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Purpose: To develop and validate a simple, rapid and inexpensive RP-HPLC method for the 
simultaneous estimation of paracetamol and meloxicam in tablets. 
Methods: For the analysis of the drugs, chromatographic analysis was performed on XTerra symmetry 
C18 column (100 × 4.6 mm, 5 µ particle size) with mobile phase consisting of methanol and phosphate 
buffer (pH 9.2) in the ratio of 50:50 v/v, at a flow rate of 0.8 mL/min and eluents monitored at 244 nm. 
The method was validated for linearity, accuracy, precision, robustness and application for assay as per 
International Conference on Harmonization (ICH) guidelines. 
Results: The retention times of paracetamol and meloxicam were 2.467 and 4.971 min, respectively. 
The calibration curves of peak area versus concentration, which was linear from 5 - 60 µg/mL for 
paracetamol and 1 - 12 µg/mL for meloxicam, had regression coefficient (r
2
) greater than 0.999. The 
method had the requisite accuracy, precision, and robustness for simultaneous determination of 
paracetamol and meloxicam in tablets. 
Conclusion: The proposed method is simple, low-cost, accurate, precise and can be successfully 
employed in routine quality control for the simultaneous analysis of paracetamol and meloxicam in 
tablets. 
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INTRODUCTION 
 
Chemically, Paracetamol (PARA), shown in 
Figure 1A, is N-(4-hydroxy phenyl) 
acetamide. It is a well known analgesic drug, 
which is very effective for the relief of pain 
and fever. The mechanism of action of 
paracetamol is due to inhibition of 
cyclooxygenase (COX) enzyme and 
prostaglandin synthesis in the central 
nervous system (CNS). It acts directly on 
hypothalamus for the regulation of elevated 
body temperature [1,2]. Meloxicam (MEL), 
shown in Fig 1B, is chemically, 4-hydroxy-2-
methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-ben-
zothaizine-3-carboxamide-1, 1-dioxide. It is 
used for the treatment of osteoarthritis, 
rheumatoid arthritis, and pauciarticular and 
polyarticular course juvenile rheumatoid 
arthritis. Its analgesic, antipyretic and anti-
inflammatory activity is due to the inhibition of 















Figure 1: Chemical structures of paracetamol (A) 
and meloxicam (B) 
 
A survey of pertinent literature revealed that 
few HPLC [5-7], spectrophotometric [8] and 
LC-MS-MS [9] methods have been reported 
for the determination of paracetamol in 
combination with other drugs. Several 
analytical methods for the determination of 
meloxicam by flourimetry [10], capillary 
electrophoresis [11], HPLC [12-13], LC/MS
 
[14] and spectrophotometry [10] have been 
reported. Ramesh S et al reported the 
simultaneous determination of paracetamol 
and meloxicam in tablets by spectro-
photometry [15]. However, there is no liquid 
chromatographic method reported for the 
simultaneous estimation of paracetamol and 
meloxicam in tablet dosage form. The aim of 
the present work was to develop and validate 
a sensitive RP-HPLC method that can be 
applied for the simultaneous analysis of 






The chromatographic system used comprised 
of Waters 2695 binary gradient pump, with in-
built auto sampler, column oven and Waters 
2487 dual wavelength absorbance detector 
(DAD). Data integration was carried out using 
Empower-2 software. Samples were injected 
into XTerra symmetry C18 column (100 × 4.6 
mm, 5 µ particle size). A Bandline sonerex 
sonicator was used for enhancing the 
dissolution of the compounds. A Digisum DI 





Pure paracetamol (PARA) and meloxicam 
(MEL) used as working standards, were gifts 
from Aurobindo Pharma Ltd, Hyderabad, 
India. Tablets containing 7.5 mg of MEL and 
325 mg of PARA (Melodol
®
) were obtained 
from Aristo Pharmaceuticals Pvt. Ltd, India 
and used within their shelf life period. 
Methanol and water (HPLC-grade) were 
purchased from Merck, India. All other 
chemicals and reagents employed were of 





The high performance liquid chromatographic 
(HPLC) system used was operated 
isocratically with the column temperature 
maintained at 30 
o
C, using a mobile phase 
composition of methanol and phosphate 
buffer (pH adjusted to 9.2 with potassium 
hydroxide) in the ratio of 50:50 v/v at a flow 
rate of 0.8 mL/min within a run time of 7 min. 
Prior to use, the mobile phase was degassed 
by an ultrasonic bath and filtered by a 
millipore vacuum filter system equipped with 
a 0.45 µm high vacuum filter. Both drugs 
were detected and quantified at 244 nm. 
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Preparation of standard solutions 
 
The standard solutions were prepared by 
transferring 10 mg of MEL and 100 mg of 
PARA working standards into separate 100 
mL volumetric flasks. To each, 10 mL of 0.1M 
NaOH was added, and the mixture was 
sonicated to dissolve and made up to volume 
with methanol. Aliquots of these standard 
solutions were transferred using A-grade bulb 
pipettes into 100 mL volumetric flasks and 
the solutions made up to volume with mobile 
phase to give final concentrations of 1 - 12 
µg/mL and 5 - 60 µg/mL of MEL and PARA, 
respectively. 
 
Quantification of paracetamol and 
meloxicam from tablets 
 
Twenty tablets were accurately weighed and 
crushed to a fine powder in a mortar. An 
amount of the powder equivalent to one 
tablet was transferred into a 100 mL 
volumetric flask and 10 mL of 0.1M NaOH 
was added to it. The mixture was sonicated 
to dissolve and then made up to volume with 
methanol. Following 15 min of mechanical 
shaking, it was kept in an ultrasonic bath for 5 
min, and the solution filtered through a 0.45 
µm filter paper. Suitable aliquots of the 
filtered solution were transferred to a 
volumetric flask and made up to volume with 
mobile phase to yield concentrations of MEL 
(1.0 µg/mL) and PARA (43.33 µg/mL). A 20 
µL volume of the sample solution was 
injected into the chromatographic system, six 
times, under optimized chromatographic 
conditions. The peak areas were measured 
at 244 nm and concentrations in the samples 
were determined by interpolation from 





The method was validated in accordance with 
ICH guidelines [16]. The parameters 
assessed were linearity, accuracy, limit of 
detection (LOD), limit of quantification (LOQ), 




Twelve different concentrations of the mixture 
of PARA and MEL were prepared for linearity 
studies and injected into chromatographic 
system (n = 3). The responses were 
measured as peak areas.  
 
Detection limit and quantitation limit 
 
The limit of detection (LOD) and limit of 
quantitation (LOQ) were calculated according 
to Eqs 1 and 2, respectively.  
 
LOD = 3.3(SD)/S ……………………….. (1) 
 
LOQ = 10(SD)/S ………………………….. (2) 
 
where SD is the standard deviation of 
response (peak area) and S is the average of 




The accuracy was carried out by adding 
known amounts of each analyte 
corresponding to three concentration levels 
(50, 100 and 150 %) of the labeled claim to 
the excipients. At each level, three 
determinations were performed and the 
results were recorded. Accuracy was 
expressed as percent analyte recovered by 




The precision of an analytical method is the 
degree of agreement among the individual 
test results, when the method is applied 
repeatedly to multiple sampling of 
homologous samples. The precision of the 
method was checked by repeatability of 
injection, repeatability (intra-day), 
intermediate precision (inter-day) and 
reproducibility. Injection repeatability was 
studied by calculating the percentage relative 
standard deviation (%RSD) for ten 
determinations of peak areas of PARA (32.5 
µg/mL) and MEL (7. 5µg/mL), performed on 
the same day. For both intra-day and inter-
day variation, standard solutions of PARA 
(16.25, 32.5 and 48.75 µg/mL) and MEL 
(3.75, 7.5 and 11.25 µg/mL) were injected in 
triplicate.  
Induri et al  
Trop J Pharm Res, August 2011;10 (4): 478 
Robustness 
 
The robustness of the proposed method was 
determined by carrying out the analysis, 
during which mobile phase composition 
(concentration of methanol was varied by ± 2 
%), and buffer pH (varied by ± 0.1) were 
altered and the peak areas and retention 




A typical chromatogram recorded at 244 nm 
is shown in Figure 2. The retention times of 
PARA and MEL at a flow rate of 0.8 mL/min 
were 2.467 and 4.971 min, respectively. The 
analyte peaks were well resolved and free 




Figure 2: A typical chromatogram of paracetamol  






To ensure the validity of the system and 
analytical method, system suitability test was 
performed. Percent relative standard 
deviation (%RSD) of the retention times (RT) 
and peak areas of PARA and MEL from the 
six consecutive injections of the standard 
solutions were 0.219 and 0.133, and 0.146 
and 0.196, respectively. The tailing factor for 
PARA and MEL peaks were 1.38 and 1.12, 
respectively, thus reflecting good peak 
symmetry. The resolution (Rs) between 
PARA and MEL was 9.62, indicating good 
separation of both analytes from each other. 
 
The theoretical plate no. for PARA and MEL 
were 3048 and 3637, respectively, thus 




The calibration curve obtained by plotting 
peak area against concentration showed 
linearity in the concentration range of 5 - 60 
µg/mL for PARA and 1 - 12 µg/mL for MEL 
(Table 1). The regression coefficients of 
PARA (r
2 
= 0.9991) and MEL (r
2 
= 0.9997) 
indicate a good linear relationship between 
peak area and concentration over a wide 
range.  
 
Detection limit and quantitation limit 
 
LOD for PARA and MEL was 0.13 and 0.03 
µg/mL, respectively, while LOQ was 
0.39µg/mL and 0.11µg/mL, respectively (see 




The mean recovery obtained for PARA and 





Results for repeatability and intermediate 
precision, expressed as %RSD, results were 
given in Table 1. The low values of %RSD 
indicate that the method is precise. Injection 
repeatability values of PARA and MEL were 
0.907 and 0.502, respectively. Reproducibility 
was checked by analyzing the samples by 
another analyst using same instrument and 
same laboratory. There was no significant 
difference between the %RSD values, which 





There was no significant change in the peak 
areas and retention times of PARA and MEL 
when the organic strength and pH of buffer 
were changed. The low values of %RSD 
indicate that the method was robust (Table 
2). 
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Table 1: Validation parameters and data for proposed method 
 
 
Results Validation parameter 
PARA MEL 
Linearity 5-60 µg/mL 1-12 µg/mL 
Regression line y = 137893 x + 580387 y = 72394 x + 28467 
Regression coefficient (r
2
) 0.9991 0.9997 
Limit of detection (µg/mL) 0.13 0.03 
Limit of quantitation (µg/mL) 0.39 0.11 
Accuracy  (% recovery)* 100.28 99.82 
Precision   
Repeatability of injection (%RSD)** 0.907 0.502 
Intra-day precision (%RSD)* 0.666 0.687 
Inter-day precision (%RSD)* 0.718 0.766 
Reproducibility   
Intra-day precision (%RSD)* 0.809 0.533 
Inter-day precision (%RSD)* 0.897 0.452 
System suitability parameter   
Peak area (%RSD) 0.133 0.196 
Retention time (%RSD) 0.219 0.146 
Tailing factor 1.38 1.12 
Number of theoretical plates 3048 3637 
Resolution  9.62 




Table 2: Results for robustness of the proposed method 
 
 
Peak area Retention time 
Parameter Original Used Analyte Mean±SD (n=3) RSD (%) Mean±SD 
(n=3) 
RSD (%) 
49 3241676±14588 0.458 2.427± 0.016 0.641 
50 3293060±3890 0.118 2.477± 0.005 0.214 
51 
PARA 
32520603±33738 1.037 2.564± 0.008 0.302 
49 310362±1452 0.468 5.022± 0.036 0.707 




310130± 1827 0.589 4.877± 0.012 0.248 
9.1 3247733± 22101 0.681 2.46± 0.009 0.35 
9.2 3294380± 3694 0.112 2.478± 0.005 0.182 
9.3 
PARA 
3254849± 17345 0.533 2.427± 0.016 0.647 
9.1 310683± 545 0.176 5.041± 0.054 1.077 
9.2 312400± 742 0.238 4.98± 0.005 0.103 
pH (Buffer) 9.2 
9.3 
MEL 
310656± 814 0.262 4.898± 0.01 0.194 
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Table 3: Assay results for paracetamol and meloxicam in tablets 
 
Product Analyte 





RSD (%) SEM 
Paracetamol       325 100.14±0.33 0.3302 0.135 
Melodol 
Meloxicam       7.5 99.84±0.24 0.2395 0.0976 
 
* n = 6; SEM = standard error of mean 
 
Quantification of paracetamol and 
meloxicam in tablets 
 
The proposed method was applied to the 
simultaneous determination of paracetamol 
and meloxicam in tablets. The results of the 
assay yielded 100.14 ± 0.33 % for PARA and 
99.84 ± 0.24 % for MEL, of label claim of the 
tablets. The assay results show that the 
method was selective for the simultaneous 
determination of PARA and MEL without 
interference from the excipients used in the 
tablet dosage form. The results are shown in 




In order to achieve simultaneous elution of 
the two components, initial trails were 
performed with the objective of selecting 
adequate and optimum chromatographic 
conditions. Parameters, such as ideal mobile 
phase and their proportions, detection 
wavelength, optimum pH, different columns 
and concentration of the standard solutions 
were carefully studied. Several solvents were 
tested in varying proportions, including 
acetonitrile, methanol, water and buffers with 
different pH values. Finally, a mixture of 
methanol and phosphate buffer (adjusted to 
pH 9.2 with potassium hydroxide) in the ratio 
of 50:50 v/v was selected as the optimum 
mobile phase.  
 
Generally, assay methods are relatively time-
consuming and involve expensive 
instrumentation not readily accessible to 
many groups. Therefore, our goal was to 
develop a relatively rapid and low-cost assay 
that could be performed at any laboratory 
with adequate HPLC instrumentation. The 
RP-HPLC method, as described, was 
validated and successfully employed for the 
simultaneous quantification of PARA and 
MEL in tablets. There is need to consider the 
successive steps for the development of RP-
HPLC method. In particular, the problems 
relating to the standardization of sample 
preparations and selection of mobile phase 
needs to be emphasized. The optimized 
chromatographic conditions were selected 
based on sensitivity, retention time, peak 
shape and baseline drifts. The method was 
selective for the determination of PARA and 
MEL since no interfering peaks appeared 
near the retention time of the compounds of 
interest. 
 
The method was validated in terms of 
linearity, accuracy, precision, LOD, LOQ and 
robustness as per ICH guidelines. Adequate 
resolution between PARA and MEL peaks 
showed the efficiency of the method based 
on its capacity to identify and determine each 
analyte at the same time with no interference. 
The LOD and LOQ values were low which 
indicates that the method is sensitive. The 
accuracy data show that the method is 
accurate within the desired range. The 
method was robust as minor changes in the 
chromatographic parameters did not bring 
about any significant changes in peak area 




The developed method for the simultaneous 
determination of paracetamol and meloxicam 
has the advantages of sensitivity, accuracy, 
precision and low cost. The non-interference 
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of tablet excipients makes the method 
suitable for the simultaneous determination of 
these drugs in tablets, and hence can be 
used for routine quality control of 
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